To further explore the inflammatory profile, a gene expression analysis was performed on biopsies from control individuals (CTR), patients with active CD (CDA), and patients with CD in remission (CDR), all treated with RvD2 or infliximab (anti-TNFα). The gene discussed is TNF; the disease is congenital dyserythropoietic anemia.